7031-65-4

Usage

Uses

Used in Pharmaceutical Industry:
2,3-dihydro-1,4-benzodioxin-2-ylmethyl methanesulfonate is used as a protecting group in the synthesis of pharmaceutical compounds. It serves to block reactive functional groups, thereby preventing unwanted side reactions that could affect the desired outcome of the synthesis process. This protection allows for more controlled and selective reactions, enhancing the yield and purity of the final product.
Used in Organic Synthesis:
In the field of organic synthesis, 2,3-dihydro-1,4-benzodioxin-2-ylmethyl methanesulfonate is employed as a versatile reagent and protecting group. Its ability to shield reactive sites on molecules is crucial for complex organic reactions, ensuring that specific functional groups are selectively modified without affecting others. This selective protection is essential for the successful synthesis of complex organic compounds and contributes to the development of novel organic materials and pharmaceuticals.

Upstream product

• 124-63-0 methanesulfonyl chloride 
• 3663-82-9 2-hydroxymethyl-2,3-dihydrobenzo[1,4]dioxin 

Downstream Products

• 1613316-35-0 C₂₈H₃₁NO₆S₂ 
• 1613316-01-0 C₂₀H₁₆O₆ 
• 1613316-00-9 C₂₀H₁₆O₆ 
• 1613315-98-2 C₂₀H₁₆O₅S 
• 1613315-96-0 C₂₀H₁₆O₅S 
• 1613315-90-4 C₂₁H₁₈O₆ 
• 1613315-88-0 C₂₁H₁₈O₆ 
• 1613315-86-8 C₂₁H₁₈O₅S 
• 1613315-85-7 C₂₁H₁₈O₅S 
• 1613316-38-3 C₂₈H₃₁NO₇S 
• 1613316-37-2 C₂₈H₃₁NO₇S 
• 1613316-36-1 C₂₈H₃₁NO₆S₂ 
• 1613316-32-7 C₁₇H₁₅BrO₅ 
• 76335-54-1 1-[(2,3-dihydro-4H-1,4-benzodioxin)-2-ylmethyl]-4-(4-methoxy-benzoyl)piperidine 

Relevant academic research and scientific papers

A short entry to enantiopure 2-substituted 1,4-benzodioxanes by efficient resolution methods

(R)-1,4-Benzodioxane-2-carboxilic acid (R)-1 was obtained by resolution of the racemic acid 1 with stoichiometric or nonstoichiometric (+)- dehydroabietylamine (+)-2 in high chemical yield and enantiomeric excess. (S)-1 was isolated from the mother liquors of the crystallisation of (R)-1·(+)-2 and its enantiomeric excess maximised by recrystallisation procedures involving a precipitation under kinetic control or, alternatively, by conversion into the methyl ester followed by a single crystallisation. The different mechanisms of the two S enrichments is well explained by the binary phase diagrams of the acid and of the ester, which show that the former is a racemic compound, whereas the latter a conglomerate. The DSC analyses were extended to 2-hydroxymethyl- and 2-mesyloxymethyl-1,4-benzodioxane, establishing that the alcohol forms a racemic compound, while its mesyl ester a conglomerate. On the basis of these results, different resolution strategies can be designed to obtain useful homochiral 2-substituted 1,4-benzodioxanes coupling the resolution of 1 via diastereomeric salt formation with the enantiomeric enrichments by recrystallisations, preferably of its conglomerate forming derivatives.